Search

Search Results

• AUTOLOGOUS STEM CELL TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA STILL A VALID TREATMENT OPTION, OR IS THE GAME OVER ?

  Fabienne McClanahan, Peter Dreger

  e2012071

  2012-11-06

  https://doi.org/10.4084/mjhid.2012.071

  2518

  PDF: 826

  HTML: 1693

• RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CHEMOIMMUNOTHERAPY, TREATMENT UNTIL PROGRESSION WITH MECHANISM-DRIVEN AGENTS OR FINITE-DURATION THERAPY?

  Antonio Cuneo, Robin Foà

  e2019024

  2019-02-27

  https://doi.org/10.4084/mjhid.2019.024

  2734

  PDF: 1669

  HTML: 266

• MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS

  Elena Maino, Anna Maria Scattolin, Piera Viero, Rosaria Sancetta, Anna Pascarella, Michele Vespignani, Renato Bassan

  e2015001

  2015-01-01

  https://doi.org/10.4084/mjhid.2015.001

  2325

  PDF: 1340

  HTML: 17099

  Bassan Fig.1: 147

  Bassan Fig.2: 161

  Bassan Fig.4: 143

  Fig.3: 197

• THERAPY-RELATED MYELOID NEOPLASMS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND WALDENSTROM MICROGLOBULINEMIA

  Francesca Ricci, Alessandra Tedeschi, Marco Montillo, Enrica Morra

  e2011031

  2011-07-08

  https://doi.org/10.4084/mjhid.2011.031

  2303

  PDF: 956

  HTML: 2394

• CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA CAR-T; Large B Cell Lymphoma; Salvage Therapy,

  Ugo Testa, Giuseppe Leone, Elvira Pelosi, Dr. Germana Castelli, Prof. Hohaus

  e2023066

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.066

  3757

  PDF: 1477

  HTML: 189

• “IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”

  Sara Martinelli, Antonio Cuneo, Gian Matteo Rigolin

  e2016047

  2016-10-15

  https://doi.org/10.4084/mjhid.2016.047

  4028

  PDF: 1061

  HTML: 3604

  Untitled: 178

  Cneo. Fig.1: 115

  Untitled: 108

  Untitled: 129

  Untitled: 136

• FOLLICULAR LYMPHOMA: THE MANAGEMENT OF ELDERLY PATIENT

  Alessia Castellino, Umberto Vitolo

  e2017009

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.009

  4460

  PDF: 1652

  HTML: 4067

  Tables and Images: 234

• The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY

  Michele Bibas

  e2024015

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.015

  1819

  PDF: 1691

  HTML: 901

• INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  AnnaMaria Nosari

  e2012070

  2012-11-05

  https://doi.org/10.4084/mjhid.2012.070

  3356

  PDF: 1370

  HTML: 2676

• GREEK CONSENSUS ON CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATMENT

  Sotirios Sachanas, Theodoros Vassilakopoulos, Maria Angelopoulou, sotirios Papageorgiou, Emmanouil Spanoudakis, Maria Bouzani, Maria Dimou, Panagiotis Panagiotidis

  e2025014

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.014

  1411

  HTML: 161

  PDF: 884

• NOVEL DRUGS IN FOLLICULAR LYMPHOMA

  Giuseppe Rossi, Antonella Anastasia

  e2016061

  2016-11-01

  https://doi.org/10.4084/mjhid.2016.061

  4361

  PDF: 1530

  HTML: 1561

  Untitled: 240

• WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 1: EPIDEMIOLOGY, PATHOGENESIS, CLINICOPATHOLOGIC CHARACTERISTICS, DIFFERENTIAL DIAGNOSIS, RISK STRATIFICATION, AND CLINICAL PROBLEMS

  Michele Bibas, Shayna Sarosiek, Jorge J. Castillo

  e2024061

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.061

  2889

  PDF: 3266

  HTML: 561

• WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE

  Maddalena Mazzucchelli, Anna Maria Frustaci, Marina Deodato, Roberto Cairoli, Alessandra Tedeschi

  e2018004

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.004

  7682

  PDF: 2449

  HTML: 1742

  Table 1.: 217

  Table 2.: 228

  Table 3.: 211

  Table 4.: 210

• BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

  Lorenzo Falchi, Jessica M Baron, Carrie Anne Orlikowski, Alessandra Ferrajoli

  e2016011

  2016-02-10

  https://doi.org/10.4084/mjhid.2016.011

  4368

  PDF: 1493

  HTML: 3627

• DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES

  Prof. Giuseppe Leone, Emiliano Fabiani, Maria Teresa Voso

  e2022030

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.030

  1409

  HTML: 478

  PDF: 839

• Lenalidomide and temozolomide combination in a very elderly patient with CNS relapse of diffuse large b-cell lymphoma.

  Emanuele Cencini, Alberto Fabbri, Umberto Arrigucci, Alfonso Cerase, Monica Bocchia

  e2017040

  2017-06-16

  https://doi.org/10.4084/mjhid.2017.040

  3454

  PDF: 1050

  HTML: 1009

  Figure 1: 178

• BRUTON’S TYROSINE KINASE (BTK) MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A CLINICAL VIEW.

  Stefano Molica

  e2025053

  2025-06-29

  https://doi.org/10.4084/MJHID.2025.053

  1641

  PDF: 936

  HTML: 141

• WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 2- FOCUS ON THERAPY

  Michele Bibas, Shayna Sarosiek , Jorge Castillo

  e2025015

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.015

  2593

  PDF: 2038

  HTML: 231

• INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISORDERS IN THE ERA OF TARGET DRUGS

  Livio Pagano, Davide Facchinelli, Dr.

  e2018063

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.063

  2077

  PDF: 1127

  HTML: 228

• ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN THE TREATMENT OF CHRONIC LYMPHOCITIC LEUKEMIA : WHY AND WHEN ?

  Maria L. Delioukina, Stephen J. Forman

  e2010018

  2010-06-30

  https://doi.org/10.4084/mjhid.2010.018

  1262

  PDF: 798

  HTML: 546

• THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.

  Francesco Maura, Lucia Farina, Paolo Corradini

  e2016045

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.045

  4097

  PDF: 1164

  HTML: 1996

  Fig.1: 219

  Fig. 2: 113

  Table 1: 207

  Table2: 225

  Table 3: 204

• APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  Tadeusz Robak

  e2010011

  2010-05-07

  https://doi.org/10.4084/mjhid.2010.011

  1680

  PDF: 658

  HTML: 2437

• COINCIDENCE OR CONNECTION? REVISITING THE RELATIONSHIP BETWEEN MASTOCYTOSIS AND LYMPHOMA

  Antonio Frolli, Cristina Papayannidis, Carmen Fava, Martina Bullo, Selene Grano, Valentina Bonuomo, Daniela Gottardi, Guido Parvis, Beatrice Casadei, Daniela Cilloni

  e2026047

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.047

  209

  PDF: 224

  HTML: 18

• AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AGGRESSIVE LYMPHOMAS

  Giuseppe Visani, Paola Picardi, Patrizia Tosi, Alessandro Isidori

  e2012075

  2012-11-07

  https://doi.org/10.4084/mjhid.2012.075

  2608

  PDF: 880

  HTML: 2126

• LIMITED STAGE FOLLICULAR LYMPHOMA: THE ROLE OF RADIATION THERAPY.

  Andrea Riccardo Filippi

  e2016041

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.041

  3744

  PDF: 1120

  HTML: 2376

  Figure 1: 211

• CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL

  Ugo Testa, Dr. Elvira Pelosi, Dr. Germana Castelli, Dr. Alberto Fresa, Prof. Luca Laurenti

  e2024045

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.045

  3725

  PDF: 1629

  HTML: 81

• CLINICAL ASPECTS AND THERAPY OF SPORADIC BURKITT LYMPHOMA

  Livio Pagano, Morena Caira, Caterina Giovanna Valentini, Luana Fianchi

  e2009030

  https://doi.org/10.4084/mjhid.2009.030

  1324

  PDF: 608

  HTML: 3105

• UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN FOLLICULAR LYMPHOMAS

  Mónica Cabrero, Alba Redondo, Alejandro Martin, Dolores Caballero

  e2012074

  2012-11-07

  https://doi.org/10.4084/mjhid.2012.074

  2187

  PDF: 745

  HTML: 1077

• CIRCCTNNA1 IS UPREGULATED IN MANTLE CELL LYMPHOMA AND PREDICTS POOR SURVIVAL BY SPONGING MIR-34A TO INCREASE CELL PROLIFERATION.

  Xuebing Jing, Cong Lu, Chao Song, Qingkun Han

  e2022047

  2022-06-29

  https://doi.org/10.4084/MJHID.2022.047

  676

  PDF: 530

  HTML: 225

• IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?

  Giuseppe Gritti, Chiara Pavoni, Alessandro Rambaldi

  e2017010

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.010

  3408

  PDF: 1300

  HTML: 2231

  Fi.1 Gritti.Rambaldi: 210

• Is laboratory monitoring useful in DOACs management?

  Mario Biglietto, Rosaria Mormile, Matteo Totaro, Maria Laura Bisegna, Cristina Santoro, Antonio Chistolini

  e2025019

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.019

  870

  PDF: 817

  HTML: 112

• Burkitt lymphoma as fourth neoplasia in a patient affected by Cowden Syndrome with a novel PTEN germline pathogenic variant

  Eugenio Galli, Francesco D’Alò, Annarosa Cuccaro, Eleonora Alma, Elena Maiolo, Fulvia Brugnoletti, Luigi Maria Larocca, Marcella Zollino, Andrea Paolo Bacigalupo, Stefan Hohaus

  e2020034

  2020-06-28

  https://doi.org/10.4084/mjhid.2020.034

  1303

  PDF: 605

  HTML: 225

• CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS CAR-T and Follicular Lymphoma

  Ugo Testa, Francesco D'Alò, Elvira Pelosi, Germana Castelli, Giuseppe Leone

  e2024012

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.012

  2369

  PDF: 1864

  HTML: 153

• NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL

  Dimitar Efremov, Adrian Wiestner, Luca Laurenti

  e2012067

  2012-10-09

  https://doi.org/10.4084/mjhid.2012.067

  2570

  PDF: 854

  HTML: 8911

  Efremov 1: 237

  Efremov 2: 203

• PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations

  Michele Bibas

  e2024007

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.007

  3603

  PDF: 2524

  HTML: 1502

• SYSTEMIC FRONT LINE THERAPY OF FOLLICULAR LYMPHOMA: WHEN, TO WHOM AND HOW

  Francesca Pavanello, Sara Steffanoni, Michele Ghielmini, Emanuele Zucca

  e2016062

  2016-11-06

  https://doi.org/10.4084/mjhid.2016.062

  3795

  PDF: 1076

  HTML: 2076

• CHLORAMBUCIL PLUS RITUXIMAB AS FRONT-LINE THERAPY IN ELDERLY/UNFIT PATIENTS AFFECTED BY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A SINGLE-CENTRE EXPERIENCE.

  Luca Laurenti, Barbara Vannata, Idanna Innocenti, Francesco Autore, Francesco Santini, Nicola Piccirillo, Tommaso Za, Silvia Bellesi, Sara Marietti, Simona Sica, Dimitar G. Efremov, Giuseppe Leone

  e2013031

  2013-05-01

  https://doi.org/10.4084/mjhid.2013.031

  3265

  PDF: 913

  HTML: 1544

  Fig.1 CHL-R paper: 227

  Fig 2 CHL-R paper: 249

• PEDIATRIC HODGKIN LYMPHOMA IN LOW- and MIDDLE-INCOME COUNTRIES (LMICs). A NARRATIVE REVIEW Pediatric Hodgkin's lymphoma in low-income countries

  Dr, Moleti, Anna Maria Testi

  e2024078

  2024-10-31

  https://doi.org/10.4084/MJHID.2024.078

  1301

  PDF: 894

  HTML: 323

• HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN ADULTS: LOW INCIDENCE OF PRIMARY NEOPLASM AS A TRIGGER IN A CASE SERIES FROM TURKEY

  Ferhat Arslan

  e2018047

  2018-09-01

  https://doi.org/10.4084/mjhid.2018.047

  1605

  PDF: 915

  HTML: 227

  Figure 1: 181

• Impact of Sars-CoV-2 prophylaxis with tixagevimab-cilgavimab in high-risk patients with B-cell malignancies: a single-center retrospective study.

  Giovanni Manfredi Assanto ,, Matteo Totaro , Poggiali Rebecca, Delli Paoli Adele, Annechini Giorgia, D’Elia Gianna Maria, Aji Francesco, Petrucci Luigi, Fazio Francesca, Del Giudice Ilaria, Martelli Maurizio, Micozzi Alessandra, Giuseppe Gentile

  e2023061

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.061

  841

  PDF: 434

  HTML: 121